Drug pricing policy in Hungary

Zoltán Vincze, R. Zelkó, Ágnes Mészáros

Research output: Contribution to journalArticle

Abstract

Besides the political, economical and social changes that occurred in the nineties, the structure and the financing of the health care systems were also thoroughly altered in Hungary. Before the nineties the price levels of medicines were kept depressed artificially. Only a minimal part of the costs of research, development and promotion was calculated in the prices of products. The purpose of the present study was to illustrate the characteristics of the transitional period and the present status of the Hungarian Health System. The authors also described the two big groups of the subsidizing systems existing in Hungary, those of the percent based and value-limited systems.

Original languageEnglish
Pages (from-to)189-204
Number of pages16
JournalJournal of Pharmaceutical Finance, Economics and Policy
Volume12
Issue number3
DOIs
Publication statusPublished - 2003

Fingerprint

Hungary
Costs and Cost Analysis
Social Change
Pharmaceutical Preparations
Health Status
Delivery of Health Care
Research

Keywords

  • Hungarian health system
  • National Health Insurance Office
  • Percent based and value-limited subsidizing systems

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy
  • Pharmaceutical Science

Cite this

Drug pricing policy in Hungary. / Vincze, Zoltán; Zelkó, R.; Mészáros, Ágnes.

In: Journal of Pharmaceutical Finance, Economics and Policy, Vol. 12, No. 3, 2003, p. 189-204.

Research output: Contribution to journalArticle

Vincze, Zoltán ; Zelkó, R. ; Mészáros, Ágnes. / Drug pricing policy in Hungary. In: Journal of Pharmaceutical Finance, Economics and Policy. 2003 ; Vol. 12, No. 3. pp. 189-204.
@article{853cf4c8cf654b599037e16df1a09d45,
title = "Drug pricing policy in Hungary",
abstract = "Besides the political, economical and social changes that occurred in the nineties, the structure and the financing of the health care systems were also thoroughly altered in Hungary. Before the nineties the price levels of medicines were kept depressed artificially. Only a minimal part of the costs of research, development and promotion was calculated in the prices of products. The purpose of the present study was to illustrate the characteristics of the transitional period and the present status of the Hungarian Health System. The authors also described the two big groups of the subsidizing systems existing in Hungary, those of the percent based and value-limited systems.",
keywords = "Hungarian health system, National Health Insurance Office, Percent based and value-limited subsidizing systems",
author = "Zolt{\'a}n Vincze and R. Zelk{\'o} and {\'A}gnes M{\'e}sz{\'a}ros",
year = "2003",
doi = "10.1300/J371v12n03_01",
language = "English",
volume = "12",
pages = "189--204",
journal = "Journal of Pharmaceutical Finance, Economics and Policy",
issn = "1538-5698",
publisher = "Haworth Press Inc.",
number = "3",

}

TY - JOUR

T1 - Drug pricing policy in Hungary

AU - Vincze, Zoltán

AU - Zelkó, R.

AU - Mészáros, Ágnes

PY - 2003

Y1 - 2003

N2 - Besides the political, economical and social changes that occurred in the nineties, the structure and the financing of the health care systems were also thoroughly altered in Hungary. Before the nineties the price levels of medicines were kept depressed artificially. Only a minimal part of the costs of research, development and promotion was calculated in the prices of products. The purpose of the present study was to illustrate the characteristics of the transitional period and the present status of the Hungarian Health System. The authors also described the two big groups of the subsidizing systems existing in Hungary, those of the percent based and value-limited systems.

AB - Besides the political, economical and social changes that occurred in the nineties, the structure and the financing of the health care systems were also thoroughly altered in Hungary. Before the nineties the price levels of medicines were kept depressed artificially. Only a minimal part of the costs of research, development and promotion was calculated in the prices of products. The purpose of the present study was to illustrate the characteristics of the transitional period and the present status of the Hungarian Health System. The authors also described the two big groups of the subsidizing systems existing in Hungary, those of the percent based and value-limited systems.

KW - Hungarian health system

KW - National Health Insurance Office

KW - Percent based and value-limited subsidizing systems

UR - http://www.scopus.com/inward/record.url?scp=4744361685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4744361685&partnerID=8YFLogxK

U2 - 10.1300/J371v12n03_01

DO - 10.1300/J371v12n03_01

M3 - Article

AN - SCOPUS:4744361685

VL - 12

SP - 189

EP - 204

JO - Journal of Pharmaceutical Finance, Economics and Policy

JF - Journal of Pharmaceutical Finance, Economics and Policy

SN - 1538-5698

IS - 3

ER -